Roche reports 7 percent sales growth for Roche Holding stock

Published on 10/23/2026 at 10:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche's third-quarter sales rose 7 percent. Roche Holding stock costs EUR 424.08 on October 23, 2026, while nine-month sales rose 6 percent.

Sales growth and targets

Third-quarter sales increased 7 percent at constant exchange rates on October 22, 2026.
Jefferies raised its Roche target from CHF 230.00 to CHF 250.00 on October 12, 2026.
Roche Holding stock trades at EUR 424.08 at 10:44 a.m. CEST at Lang & Schwarz on October 23, 2026.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding (ISIN CH1499059983) reported third-quarter sales growth of 7 percent at constant exchange rates on October 22, 2026. The update confirmed the 2026 outlook while highlighting continued demand for medicines and diagnostics, according to Roche.

Three milestones shape the story

Roche said on September 30, 2026, that fenebrutinib reduced relapses by 51 percent and 58 percent in two phase III studies. On October 1, 2026, the company said giredestrant reduced the risk of disease progression or death by 44 percent and 62 percent in two patient populations. The current event came on October 22, 2026, when third-quarter sales rose 7 percent at constant exchange rates and first-nine-month group sales reached CHF 46.493 billion, compared with CHF 45.862 billion in the same period of 2025, according to Roche.

What does the target change mean?

Jefferies raised its Roche price target from CHF 230.00 to CHF 250.00 on October 12, 2026, while retaining an Underperform rating, according to Finanznachrichten. The analyst cited a 40 percent valuation premium and said giredestrant and fenebrutinib now need to deliver clinical and commercial success. That creates a clear tension in the stock case: operating sales are growing, but the pipeline must support the valuation.

Next dates for Roche investors

Roche's next listed investor event is the Berenberg Pharma CFO Series on November 2, 2026, according to its investor calendar. Roche has also proposed the election of Christophe Weber to its board at the annual general meeting on March 9, 2027, according to the October 22 release.

Stock price after the sales update

For investors, the main question is whether the 7 percent constant-currency growth can offset patent pressure and support Roche's pipeline spending. Roche reported first-nine-month Pharmaceuticals sales of CHF 36.212 billion, up 7 percent at constant exchange rates, while Diagnostics sales reached CHF 10.281 billion, up 4 percent on the same basis.

Roche Holding stock was trading at EUR 424.08 at Lang & Schwarz on October 23, 2026 at 10:44 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.